All Stories

  1. Psychiatry and sensation: the epigenetic links
  2. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  3. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  4. Dietary Intake of Polyphenols and All-Cause Mortality: A Systematic Review with Meta-Analysis
  5. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease
  6. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
  7. The epigenetics of frailty
  8. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  9. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  10. The Relationship between Oral Health-Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  11. The Relationship between Oral Health‐Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  12. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders
  13. Exploring the Association of Burning Mouth Syndrome with Depressive and Anxiety Disorders in Middle-Aged and Older Adults: A Systematic Review
  14. Processed foods and diet quality in pregnancy may affect child neurodevelopment disorders: a narrative review
  15. Retinal Microvasculature and Neural Changes and Dietary Patterns in an Older Population in Southern Italy
  16. Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study
  17. Apolipoprotein E genotype, inflammatory biomarkers, and non-psychiatric multimorbidity contribute to the suicidal ideation phenotype in older age. The Salus in Apulia Study
  18. Temporomandibular Disorders as a Risk Factor for Suicidal Behavior: A Systematic Review
  19. The challenges of anti-tau therapeutics in Alzheimer disease
  20. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
  21. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
  22. Motoric Cognitive Risk Syndrome, Subtypes and 8-Year All-Cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  23. Motoric Cognitive Risk Syndrome, Subtypes and 8-year all-cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  24. Dietary Patterns Associated with Diabetes in an Older Population from Southern Italy Using an Unsupervised Learning Approach
  25. Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review
  26. Association of Neuroretinal Thinning and Microvascular Changes with Hypertension in an Older Population in Southern Italy
  27. Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study
  28. Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study
  29. Could Epigenetics Play a Role in Suicidal Behavior in Older Age?
  30. Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
  31. COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy
  32. Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study
  33. Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy
  34. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism
  35. The relationship between epigenetics and microbiota in neuropsychiatric diseases
  36. Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy
  37. Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study
  38. The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase
  39. Social determinants of late-life depression epigenetics
  40. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
  41. Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study
  42. Corrigendum to “Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review” Neurosci. Biobehav. Rev. 95 (2018) 480–498
  43. The Challenge of Antidepressant Therapeutics in Alzheimer’s Disease
  44. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
  45. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline
  46. Time to test antibacterial therapy in Alzheimer’s disease
  47. Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia
  48. Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging
  49. The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear
  50. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
  51. Disease-modifying therapies for tauopathies: agents in the pipeline
  52. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
  53. Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer’s disease
  54. Understanding frailty to predict and prevent dementia
  55. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
  56. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke
  57. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
  58. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
  59. The Role of Biomarkers in Psychiatry
  60. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review
  61. Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life
  62. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
  63. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study
  64. CYP2D6 genotypes in revolving door patients with bipolar disorders
  65. Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review
  66. Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder
  67. Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention
  68. Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer’s Disease Versus Vascular Dementia
  69. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging
  70. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
  71. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
  72. Cognitive frailty: a potential target for secondary prevention of dementia
  73. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry
  74. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review
  75. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline
  76. An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-term Care Facilities
  77. Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer’s Disease
  78. Emerging biomarkers and screening for cognitive frailty
  79. Genetics of tailored medicine: Focus on CNS drugs
  80. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging
  81. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association
  82. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?
  83. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
  84. The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes
  85. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
  86. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders
  87. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?
  88. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
  89. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?
  90. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder
  91. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?
  92. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
  93. Alternative pharmacological treatment options for agitation in Alzheimer’s disease
  94. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease
  95. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis
  96. Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients
  97. Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance